Impact of human cytomegalovirus (CMV) infection on immune response to pandemic 2009 H1N1 influenza vaccine in healthy adults

Journal of Medical Virology

Volumn 85, Issue 9, 2013, Pages 1557-1560

  Wald, Anna ^a,b   Selke, Stacy ^a   Magaret, Amalia ^a,b   Boeckh, Michael ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b USA   (United States)

Author keywords

Antibody titer; Cytomegalovirus; Immunosenescence; Influenza vaccine

Indexed keywords

INFLUENZA VACCINE; VIRUS ANTIBODY; VIRUS ANTIGEN;

ADULT; AGED; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DOUBLE BLIND PROCEDURE; FEMALE; GEOMETRY; GROUPS BY AGE; HEMAGGLUTINATION INHIBITION TEST; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; MAJOR CLINICAL STUDY; MALE; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION; VACCINATION;

ANTIBODY TITER; CYTOMEGALOVIRUS; IMMUNOSENESCENCE; INFLUENZA VACCINE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, VIRAL; CYTOMEGALOVIRUS INFECTIONS; DOUBLE-BLIND METHOD; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 84880348553     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.23642     Document Type: Article

References (9)

1. Brunner S, Herndler-Brandstetter D, Weinberger B, Grubeck-Loebenstein B. 2010. Persistent viral infections and immune aging. Ageing Res Rev 10:362-369.
2. Cannon MJ, Hyde TB, Schmid DS. 2011. Review of cytomegalovirus shedding in bodily fluids and relevance to congenital cytomegalovirus infection. Rev Med Virol 21:240-255.
3. Chen WH, Winokur PL, Edwards KM, Jackson LA, Wald A, Walter EB, Noah DL, Wolff M, Kotloff KL. 2012. Phase 2 assessment of the safety and immunogenicity of two inactivated pandemic monovalent H1N1 vaccines in adults as a component of the U.S. pandemic preparedness plan in 2009. Vaccine 30:4240-4248.
4. den Elzen WP, Vossen AC, Cools HJ, Westendorp RG, Kroes AC, Gussekloo J. 2011. Cytomegalovirus infection and responsiveness to influenza vaccination in elderly residents of long-term care facilities. Vaccine 29:4869-4874.
5. Moro-Garcia MA, Alonso-Arias R, Lopez-Vazquez A, Suarez-Garcia FM, Solano-Jaurrieta JJ, Baltar J, Lopez-Larrea C. 2012. Relationship between functional ability in older people, immune system status, and intensity of response to CMV. Age (Dordr) 34:479-495.
6. Pawelec G, Akbar A, Beverley P, Caruso C, Derhovanessian E, Fulop T, Griffiths P, Grubeck-Loebenstein B, Hamprecht K, Jahn G, Kern F, Koch SD, Larbi A, Maier AB, Macallan D, Moss P, Samson S, Strindhall J, Trannoy E, Wills M. 2010. Immunosenescence and Cytomegalovirus: Where do we stand after a decade? Immune Ageing 7:13.
7. Powers DC, Belshe RB. 1993. Effect of age on cytotoxic T lymphocyte memory as well as serum and local antibody responses elicited by inactivated influenza virus vaccine. J Infect Dis 167:584-592.
8. Simonsen L, Taylor RJ, Viboud C, Miller MA, Jackson LA. 2007. Mortality benefits of influenza vaccination in elderly people: An ongoing controversy. Lancet Infect Dis 7:658-666.
9. Trzonkowski P, Mysliwska J, Szmit E, Wieckiewicz J, Lukaszuk K, Brydak LB, Machala M, Mysliwski A. 2003. Association between cytomegalovirus infection, enhanced proinflammatory response and low level of anti-hemagglutinins during the anti-influenza vaccination-An impact of immunosenescence. Vaccine 21:3826-3836.